Robot-assisted Procedure Versus Open Simultaneous Resection of Colorectal Cancer With Liver Metastases

Sponsor
Xu jianmin (Other)
Overall Status
Unknown status
CT.gov ID
NCT02642978
Collaborator
(none)
160
1
2
48
3.3

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of robot-assisted simultaneous resection in selected patients with sigmoid colon cancer or rectal cancer liver metastases, and compared with the traditional open procedure.

Condition or Disease Intervention/Treatment Phase
  • Procedure: RSRCLM
  • Procedure: Open
N/A

Detailed Description

The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery. The aim of this study was to present an innovative technique that is robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
micro-invasive surgerymicro-invasive surgery
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Safety and Effect of Robot-assisted Procedure Versus Open Simultaneous Resection of Colorectal Cancer: Randomized Control Trial Study
Actual Study Start Date :
Sep 1, 2015
Anticipated Primary Completion Date :
Apr 1, 2019
Anticipated Study Completion Date :
Sep 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: RSRCLM

robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).Three different liver resection procedures were chose to personalized patients. Generally, when the size of liver metastasis was ≤ 3 cm, a wedge resection was chose without Hilar vessels blocking. The segmentectomy was performed using the Glissonian approach when tumor size was among 3-5 cm, and Hilar vessels was blocked, if necessary. For resection of Couinaud's segments II and III, left lateral sectionectomy (LLS) was performed commonly. Intraoperative ultrasound can help us find intrahepatic pedicles and follow the proper resection line. When liver tumor size was more than 5 cm or more than 3 tumors with the size over 3cm, hemicolectomy was applied usually.

Procedure: RSRCLM
The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery. The aim of this study was to present an innovative technique that is robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).

Active Comparator: Open

Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis. The DFS and safety event were evaluated.

Procedure: Open
Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis

Outcome Measures

Primary Outcome Measures

  1. Surgical Complication [30 days after surgury]

    According to Clavein-Dindo complication system to calculate the complication events during 30 day after surgery

Secondary Outcome Measures

  1. Operative mortality [30 days post operatively]

    death occurred 30 days after operation

  2. Disease-free survival(DFS) [3 years disease-free survival]

    DFS was defined as from the date of randomization to the date of tumor

  3. overall survival (OS) [OS rate at 3 and 5 years after operation]

    overall survival was defined as from the date of randomization to the date of Death ;

  4. locoregional recurrence rate [3 and 5 years]

    local recurrence rate at 3 and 5 years after operation

Other Outcome Measures

  1. self reported bladder function [at postoperative 3, 6 and 1 2 months]

    This section is assessed using a self-rating scale "International prostate symptom score" (IPSS)

  2. self reported sexual function for male patients [at postoperative 3, 6 and 1 2 month]

    This section is assessed using a self-rating scale "International Index of Erectile Function" (IIEF-5).

  3. self reported sexual function for female patients [at postoperative 3, 6 and 1 2 months]

    This section is assessed using a self-rating scale "Female Sexual Function Index" (FSFI).

  4. liver function [at Day 1,3,5 after surgery]

    Serum aminotransferase will be tested in the laboratory

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age ≥ 18 and ≤ 75 years;

  2. Primary tumor has undergone histologically confirmed colon adenocarcinoma; Colon cancer was defined by the presence of the inferior pole of the tumor above the peritoneal reflection (at least 15 cm from the anal margin).

  3. Together with clinical or radiological evidence of Stage II (T3-4, N0, M0) or Stage III (T1-4, N1-2, M0) disease (according to the 2010 revision of the International Union Against Cancer primary tumor, regional nodes, metastasis (TNM) staging system);Liver metastasis was diagnosis by multidisciplinary (MDT) team base on liver Magnetic Resonance Imaging (MRI) and Positron Emission Computed Tomography (PET-CT).

  4. Performance status (ECOG) 0~1

  5. Adequate hematological function: Neutrophils≥1.5 x109/l and platelet count≥100 x109/l; hemoglobin (Hb) ≥9g/dl (within 1 week prior to randomization)

  6. Adequate hepatic and renal function: Serum bilirubin≤1.5 x upper limit of normal (ULN), alkaline phosphatase ≤5x ULN, and serum transaminase (either primary tumor, regional nodes, metastasis (AST) or ALT) ≤ 5 x ULN(within 1 week prior to randomization);

  7. Written informed consent for participation in the trial.

  8. The liver resectability was evaluated by liver surgery of MDT team, indication including: tumor number ≤ 3; the Maximum diameter of one tumor ≤ 10 cm.

Exclusion Criteria:
  1. Body mass index (BMI) more than 30 kg/m2.

  2. Serious pre-operative comorbidity, including cardiovascular disease (coronary arteriosclerosis, arrhythmia, heart failure), pulmonary dysfunction (lung emphysema, obstructive lung disease), liver insufficiency (Child-Pugh B or C), renal insufficiency (serum creatinine >2.0 mg/dl), and arterial circulation disturbance (occlusion of arterial vessels of limb in patient's history.

  3. History of accepting abdominal surgery.

  4. Liver tumor located at I or invasive the middle hepatic vein.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of General Surgery, Zhongshan Hospital, Fudan University Shanghai China 200032

Sponsors and Collaborators

  • Xu jianmin

Investigators

  • Principal Investigator: wenju chang, MD, Fudan University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xu jianmin, Fudan University, Fudan University
ClinicalTrials.gov Identifier:
NCT02642978
Other Study ID Numbers:
  • RSRCLM
First Posted:
Dec 30, 2015
Last Update Posted:
Mar 29, 2019
Last Verified:
Mar 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Xu jianmin, Fudan University, Fudan University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 29, 2019